Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carboxypeptidase B2 isoform A (CPB2)
- Target
- CPB2
- Molecular classification
- Enzyme, Peptidase M14 family, Carboxypeptidase
01
Overview
Carboxypeptidase B2 isoform A (CPB2), also known as Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) or Carboxypeptidase U (CPU), is a plasma carboxypeptidase that regulates fibrinolysis. Synthesized primarily in the liver and expressed by platelets, CPB2 is activated by thrombin/thrombomodulin or plasmin, converting it into its active form (TAFIa). TAFIa removes C-terminal lysine residues from partially degraded fibrin, inhibiting plasminogen binding and activation, thus stabilizing clots. CPB2 also converts complement component C5a into its desArg form, modulating the immune response. Dysregulation of CPB2 may impact thrombosis risk or bleeding disorders, and genetic polymorphisms can influence its function.
- Other names
- TAFICPUThrombin-Activatable Fibrinolysis InhibitorCarboxypeptidase UpCPBplasma carboxypeptidase B
02
Mechanism of action
Hydrolyzes C-terminal lysine or arginine residues from peptides/proteins, inhibiting fibrinolysis and modulating inflammatory mediators.
03
Biological functions
Regulation of fibrinolysisDownregulation of blood clot breakdownModulation of inflammatory mediatorsRegulation of coagulation cascadeImmune responseHydrolyzes C-terminal peptide bonds
04
Disease associations
ThrombosisBleeding disordersCardiovascular diseaseInflammationImmune dysregulation
05
Safety considerations
Potential for dysregulation impacting thrombosis riskPotential for dysregulation impacting bleeding disordersGenetic polymorphisms may affect function
Beyond the preview
Go deeper on Carboxypeptidase B2 isoform A (CPB2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carboxypeptidase B2 isoform A (CPB2).